Table 2 Comparison of serum lipid levels after treatment at 48 and 96 weeks.

From: Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate

 

TDF (n = 265)

TAF (n = 153)

Baseline

48 weeks

P value*

Baseline

48 weeks

P value*

TG (mg/ml)

105.29 ± 63.81

100.53 ± 63.11

0.226

114.13 ± 61.47

129.97 ± 71.16

0.004

TC (mg/ml)

168.07 ± 35.72

161.18 ± 31.72

< 0.001

183.03 ± 40.89

189.36 ± 38.64

0.01

HDL (mg/ml)

47.39 ± 14.07

46.24 ± 11.74

0.104

49.51 ± 10.91

47.02 ± 11.84

0.001

LDL (mg/ml)

89.91 ± 24.85

88.82 ± 23.73

0.337

107.13 ± 32.04

121.88 ± 34.33

< 0.001

TC/HDL

3.81 ± 1.32

3.66 ± 1.06

0.022

3.84 ± 1.13

4.32 ± 2.04

0.001

LDL/HDL

2.07 ± 0.89

2.04 ± 0.77

0.516

2.27 ± 0.84

2.78 ± 1.17

< 0.001

 

TDF (n = 238)

TAF (n = 54)

 

Baseline

96 weeks

P value*

Baseline

96 weeks

P value*

TG (mg/ml)

103.85 ± 60.85

104.29 ± 62.85

0.916

118.16 ± 80.02

126.57 ± 72

0.436

TC (mg/ml)

168.86 ± 35.1

162.53 ± 31.77

0.002

179.06 ± 43.96

183.7 ± 32.98

0.306

HDL (mg/ml)

47.11 ± 12.89

46.52 ± 12.12

0.434

47.03 ± 12.88

45.73 ± 11.09

0.35

LDL (mg/ml)

89.54 ± 25.02

92.98 ± 24

0.008

98.26 ± 31.03

115.75 ± 27.8

< 0.001

TC/HDL

3.83 ± 1.31

3.67 ± 1.06

0.016

4.11 ± 1.71

4.23 ± 1.15

0.585

LDL/HDL

2.07 ± 0.91

2.13 ± 0.81

0.135

2.28 ± 1.09

2.69 ± 0.9

0.002

  1. * the result of paired T-test.
Back to article page